Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of OROS vs IR Methylphenidate DAT Occupancy
NCT00302393Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2006
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Dopamine Transporter Receptor Occupancy at 5 hours, d and l ritalinic acid levels at 6 hours and 1 more. Started Jun 2006; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00302393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302393.